Folate supplementation during Methotrexate therapy for rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 61, 2010, Pages

  Morgan, S L ^a   Baggott, J E ^b  

^a Schools of Med and Dent U   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Folate supplementation; Methotrexate

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; FOLINIC ACID; HOMOCYSTEINE; METHOTREXATE; PLACEBO; PYRIDOXINE; SALAZOSULFAPYRIDINE; ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; C REACTIVE PROTEIN; FIBRINOGEN; LEFLUNOMIDE; PREDNISOLONE;

ADD ON THERAPY; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BLOOD TOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; ECTOPIC PREGNANCY; FOLIC ACID DEFICIENCY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; LIVER ENZYME BLOOD LEVEL; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEDICAL SOCIETY; META ANALYSIS (TOPIC); NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; STOMATITIS; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID METABOLISM; AMINOTRANSFERASE BLOOD LEVEL; CLINICAL EFFECTIVENESS; DIARRHEA; DISEASE CONTROL; MOUTH ULCER; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN BLOOD LEVEL; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; EVIDENCE-BASED MEDICINE; FOLIC ACID; HUMANS; LEUCOVORIN; METHOTREXATE; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME; VITAMIN B COMPLEX;

EID: 78650567202     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. McKENDRY R: The remarkable spectrum of methotrexate toxicities. Rheum Dis Clin North Am 1997;23:939-54.
2. CASSERLY CM, STANGE KC, CHREN M-M.: Severe megaloblastic anemia in a patient receiving low-dose methotrexate for psoriasis. J Am Acad Dermatol 1993;29:447-80.
3. LIM A Y N, GAFFNEY K, SCOTT D G I: Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology 2005;44:1051-55.
4. MACKINNON SK, STARKEBAUM G, WILLKENS RF: Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 1985;15:119-26.
5. KALANTIZIS A, MARSHMAN Z, FALCONER DT, MORGAN PR, ODELL EW: Oral effects of low-dose methotrexate treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;100:52-62.
6. VAN EDE AE, LAAN R F J M, BLOM HI, DE ABREU RA, VAN DE PUTTE L B A: Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998;27:277-92.
7. WEINBLATT ME, FRASER P: Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum 1989;32:1592-6.
8. ANDERSEN LS, HANSEN EL, KNUDSEN JB, WESTER JU, HANSEN G V O, HANSEN TM: Prospectively measured red cell folate levels in methotrexate treated patients with rheumatoid arthritis: relation to withdrawal and side effects. J Rheumatol 1997;24:830-7.
9. IMOKAWA S, COLBY TV, LESLIE KO, HELMERS RA: Methotrexate pneumonitis: a review of the literature and histopathological findings in nine patients. Eur Respir J 2000;15:373-81.
10. KREMER J, LEE R, TOLMAN K: Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy: a prospective study with baseline and sequential biopsy samples. Arthritis Rheum. 1989;32:121-7.
11. KREMER JM, GALIVAN J, STRECKFUSS A, KAMEN B: Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients: Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986;29:832-5.
12. MORGAN SL, BAGGOTT JE, LEE JY, ALARCÓN GS: Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention J Rheumatol 1998;25:441-6.
13. ALARCON G, TRACY I, BLACKBURN W: Methotrexate in rheumatoid arthritis: Toxic effects as the major factor in limiting longterm treatment. Arthritis Rheum. 1989;32:671-6.
14. LEEB BF, WITZMANN G, OGRIS E et al.: Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients. Clin Exp Rheumatol 1995;13:459-63.
15. MORGAN SL, BAGGOTT JE, ALTZ-SMITH M: Folate status of rheumatoid arthritis patients receiving long-term, low-dose methotrexate therapy. Arthritis Rheum 1987;30:1348-56.
16. HORNUNG N, ELLINGSEN T, STENGAARD-PEDERSEN K, POULSEN JH: Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of folic acid supplement. J Rheumatol 2004;31:2374-81.
17. BUCKLEY LM, VACEK PM, COOPER SM: Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol. 1990;17:1158-61.
18. HANRAHAN PS, RUSSELL AS: Concurrent use of folinic acid and methotrexate in rheumatoid arthritis. J Rheumatol 1988;15:1078-80.
19. HUNT PG, ROSE CD, MCILVAIN-SIMPSON G, TEIANI S: The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study. J Rheumatol 1997;24:2230-2.
20. JOYCE DA, WILL RK, HOFFMAN DM, LAING B, BLACKBURN SJ: Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis 1991;50:913-4.
21. MODESTO C, CASTRO L: Folinic acid supplementation in patients with juvenile rheumatoid arthritis treated with methotrexate. J Rheumatol 1996;23:403-4. (Pubitemid 26078403)
22. MORGAN SL, BAGGOTT JE, ALARCÓN GS, KOOPMAN WJ, KRUMDIECK CL: Leucovorin versus folic acid in the treatment of methotrexate toxicity: comment on the article by Shiroky et al. Arthritis Rheum 1994;37:444-8.
23. MORGAN SL, BAGGOTT JE, VAUGHN WH et al.: The effect of folic acid supplementation on the toxicity of low-dose methotrexate treatment of rheumatoid arthritis. Arthritis Rheum 1990;33:9-18.
24. RAVELLI A, MIGLIAVACCA D, VIOLA S, RUPERTO N, PISTORIO A, MARTINI A: Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis Clin Exp Rheumatol 1999;17:625-7.
25. SHIROKY JB, NEVILLE C, ESDAILE JM et al.: Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Arthritis Rheum 1993;36:795-803.
26. STEWART KA, MACKENZIE AH, CLOUGH JD, WILKE WS: Folate supplementation in methotrexate-treated rheumatoid arthritis patients. Semin Arthritis Rheum 1991;20:332-8.
27. TISHLER M, CASPI D, FISHEL B, YARON M: The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum 1988;31:906-8.
28. VAN EDE AE, LAAN R F J M, ROOD MJ et al.: Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001;44:1515-24.
29. WEINBLATT ME, MAIER AL, COBLYN JS: Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8-week randomized placebo controlled trial. J Rheumatol 1993;20:950-2.
30. ORTIZ Z, SHEA B, SUAREZ ALMAZOR M, MOHER D, WELLS GA, TUGWELL P: The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 2000;25:36-43.
31. ORTIZ Z, SUAREZ ALMAZOR M, MOHER D, WELLS G, TUGWELL P: Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000;2: CD00951.
32. PREY S, PAUL C: Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol 2008;160:622-8.
33. HOEKSTRA M, VAN EDE AE, HAAGSMA CJ et al.: Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:423-426.
34. KENT PD, LUTHRA HS, MICHET C: Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis. J Rheumatol 2004;31:1727-31.
35. GRIFFITH SM, FISHER J, CLARKE S et al.: Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? Rheumatology 2000;39:1102-9.
36. TAKACS P, RODRIGUEZ L: High folic acid levels and failure of single-dose methotrexate treatment in ectopic pregnancy. Int J Gynaecol Obstet 2005;89:301-2.
37. WEGKAMP A, DE VOS WM, SMID EJ: Folate overproduction in Lactobacillus plantarum WCFS1 causes methotrexate resistance. FEMS Microbiol Lett 2009;297:261-5.
38. DERVIEUX T, FURST D, LEIN DO: Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 2005;64:1180-5.
39. STAMP LK, O'DONNELL JL, CHAPMAN PT et al.: Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum 2010;62:359-68.
40. BRESSOLLE F, KINOWSKI JM, MOREL J, POULY B, SANY J, COMBE B: Folic acid alters methotrexate availability in patients with rheumatoid arthritis. J Rheumatol 2000;27:2110-4.
41. HIRAGA Y, YUHKI Y, ITOH K, TADANO K, TAKAHASHI Y, MUKAI M: Pharmacokinetics and efficacy of low-dose methotrexate in patients with rheumatoid arthritis. Mod Rheumatol 2004;14:135-142.
42. YAMAUCHI P, RIZK D, KORMEILIT, PATNAIK R, LOWE N: Current systemic therapies of psoriasis: Where are we now? J Am Acad Dermatol 2003;49: S66-77.
43. ARABELOVIC S, SAM G, DALLAL GE et al.: Preliminary evidence shows the folic acid fortification of the food supply is associated with higher methotrexate dosing in patients with rheumatoid arthritis J Am Coll Nutr 2007;26:453-55.
44. EMERY P, BREEDVELD FC, LEMMEL EM et al.: A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000;39:655-65.
45. SCHIFF MH: Leflunomide versus methotrexate: a comparison of the European and American experience. Scand J Rheumatol Suppl 1999;112:31-5.
46. STRAND V, COHEN S, SCHIFF M et al.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999;159:2542-50.
47. KHANNA D, PARK GS, PAULUS HE et al.: Reduction of the efficacy of methotrexate by the use of folic acid - post hoc analysis from two randomized controlled studies. Arthritis Rheum 2005;52:3030-8.
48. MORGAN SL, BAGGOTT JE, ALARCÓN GS: Effect of folic acid supplementation on the efficacy of methotrexate treatment in rheumatoid arthritis: comment on the article by KHANNA et al. Arthritis Rheum 2006;54:1708-9.
49. STRAND V, MORGAN SL, BAGGOTT JE, ALARCÓN GS: Folic acid supplementation and methotrexate efficacy: comment on articles by SCHIFF, EMERY et al. and others. Arthritis Rheum 2000;43:2615-6.
50. HOEKSTRA M, VAN DE LAAR M A F J, BERNELOT MOENS HJ, KRUIJSEN MW, HAAGSMA CJ: Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis. J Rheumatology 2003;30:2325-9.
51. McCULLY KS, WILSON RB: Homocysteine theory of arteriosclerosis. Atherosclerosis 1975;22:215-27.
52. CIACCIO M, BELLIA C: Hyperhomocysteinemia and cardiovascular risk: effect of vitamin supplementation in risk reduction. Curr Clin Pharmacol 2010;5:30-6.
53. HEINZ J, KROPF S, DONROSE U et al.: B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. Circulation 2010;121:1432-8.
54. STUDY OF THE EFFECTIVENESS OF ADDITIONAL REDUCTIONS IN CHOLESTEROL AND HOMO-CYSTEINE (SEARCH) COLLABORATIVE GROUP: Effects of homocysteine-lowering with folic acid plus vitamin B12 vs. placebo on mortality and major morbidity in myocardial infarction survivors. A randomized trial. J Am Med Assoc. 2010;303:2486-94.
55. PARK CS, IHN S-H, YOO K-D et al.: Relation between C-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among health adults in the USA. Am J Cardiol 2010;105:1284-88.
56. YXFELDT A, WALLBERG-JONSSON S, HULTDIN J, RANTAPAA-DAHLQVIST S: Homocysteine in patients with rheumatoid arthritis in relation to inflammation and B-Vitamin treatment. Scand J Rheumatol 2003;32:205-10.
57. SLOT O: Changes in plasma homocysteine in arthritis patients starting treatment with lowdose methotrexate subsequently supplemented with folic acid. Scan J Rheumatol 2001;30:305-7.
58. VAN EDE AE, LAAN R F J M, BLOM HJ et al.: Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology 2002;41:658-65.
59. HOEKSTRA M, HAAGSMA CJ, DOELM ANCJA, VAN DE LAAR M A F J: Intermittent rises in plasma homocysteine in patients with rheumatoid arthritis treated with higher dose methotrexate. Ann Rheum Dis 2005;64:141-3.
60. HAAGSMA CJ, BLOM HJ, VAN RIEL P L C M: Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentration in patients with rheumatoid arthritis. Ann Rheum Dis 1999;58:79-84.
61. TIFTIKCI A, OZDEMIR A, TARCIN O et al.: Influence of serum folic acid levels on plasma homocysteine concentrations in patients with rheumatoid arthritis. Rheumatol Int 2006;26:191-4.
62. JENSEN OK, RASMUSSEN C, MOLLERUP F et al.: Hyperhomocysteinemia in rheumatoid arthritis: Influence of methotrexate treatment and folic acid supplementation. J Rheumatol 2002;29:1615-8.
63. MORGAN SL, OSTER RA, LEE JY, ALARCÓN GS, BAGGOTT JE: The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis. Arthritis Rheum 2004;50:3104-11.
64. CANHAO H, SANTOS MJ, COSTA L et al.: Recomendacoes Portuguesas para utlilzaco de meotrexato no tratamento de doenca reumaticas. Acta Reumatol Port. 2009;34:78-95.
65. DIAZ-BORJON A: Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. Drugs Aging 2009;26:273-93.
66. NIEHUES T, LANKISCH P: Recommendations for the use of methotrexate in juvenile idiopathic arthritis. Pediatr Drugs 2006;8:347-356.
67. PAVY S, CONSTANTIN A, PHAM T et al.: Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine. 2006;73:388-95.
68. VISSER K, KATCHAMART W, LOZA E et al.: Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international